Skip to main content

Table 1 Baseline characteristics of the patients

From: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

Variable

Patients (N = 39)

Age (years), median (range)

58 (30–68)

Gender, N (%)

 Male

19 (48.7)

 Female

20 (51.3)

ECOG performance status, N (%)

 0

12 (30.8)

 1

27 (69.2)

Non resectable factors, N (%)

 N3 lymph node metastasis

2 (5.1)

 Distant lymphatic metastasis

4 (10.3)

 Invasion of peripheral organs (T4b)

4 (10.3)

 Liver metastasis

2 (5.1)

 Peritoneal carcinomatosis

27 (69.2)

Pathological type, N (%)

 Moderately differentiated adenocarcinoma

5 (12.8)

 Poorly differentiated adenocarcinoma

17 (43.6)

 Mucinous adenocarcinoma

3 (7.7)

 Signet ring cell carcinoma

14 (35.9)

Tumor site, N (%)

 Antrum gastric angle

11 (28.2)

 Gastric body

11 (28.2)

 Fundus cardia

10 (25.6)

 Diffuse whole stomach

7 (17.9)